drugset / Trial / NCT02092142
Safety and Immunogenicity of Q Fever Vaccine
Phase 2
Withdrawn
U.S. Army Medical Research and Development Command
US Army Medical Research Institute of Infectious Diseases · collab
NaSingle-groupOpen-labelPrevention
Summary
The purpose of this study is to evaluate the safety of Q Fever Vaccine, Phase I, Inactivated, Dried, NDBR 105 and collect data on incidence of occupational Q fever infection in vaccinated personnel.
Timeline
- Start
- 2006-02
- Primary completion
- 2019-02
- Completion
- 2019-12
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Q fever Vaccine | Vaccine | 30 ug | Subcutaneous |
| Subject | Q fever Vaccine | Vaccine | 0.5 ml | Subcutaneous |